Financing ·
Lyell Immunopharma raises $80M via private placement of 7.43M shares at $10.77
LYELLyell Immunopharma, Inc.
Lyell Immunopharma entered into a Securities Purchase Agreement with institutional accredited investors to sell and issue an aggregate of 7,428,040 shares of common stock in a private placement transaction. The shares were sold at a purchase price of $10.77 per share, generating total gross proceeds of approximately $80.0 million before expenses. The closing is scheduled for on or about November 4, 2026, subject to customary conditions. The company must file a registration statement within 30 days after closing to register the shares for resale. Lyell Immunopharma operates in the biotechnology industry, focusing on developing immunotherapies.